orelabrutinib combined with rituximab regimen
2024-1336
Phase 2 small_molecule active
Quick answer
orelabrutinib combined with rituximab regimen for Marginal Zone Lymphoma(MZL) is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Marginal Zone Lymphoma(MZL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active